Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Various therapies such as CAR-T and TCR-T therapies have emerged with promising outcomes. Despite its remarkable potential, CAR-T faces limitations such as antigen escape and restricted efficacy against solid tumors. On the other hand, TCR-T therapy targets intracellular antigens presented on MHC molecules, offering a broader target range but often facing MHC restriction issues and potential off-target toxicity. TRuC cells are engineered by fusing a tumor-targeting single-chain variable fragment (scFv) directly to the T-cell receptor complex, allowing for the recognition of both MHC and non-MHC-restricted antigens. By integrating the natural TCR-signaling machinery, TRuC cells are designed to provide robust and sustained anti-tumor activity.
Creative Biolabs offers comprehensive TRuC cell development services that facilitate the efficient design and engineering of TRuC cells to meet specific needs. We have developed a universal allogeneic TRuC cell platform for off-the-shelf therapeutic solutions.
Creative Biolabs has developed a TRuC platform specifically for designing TRuC constructs that optimize tumor recognition and T cell activation. By integrating bioinformatics and molecular biology tools, Creative Biolabs ensures precise scFv selection, optimal fusion to the TCR complex, and TRuC vector design. The TRuC vector design is tailored to meet the individual needs of each client, ensuring that each vector construct is highly specific and functionally potent.
Fig.1 Schematic diagram of various TRuCs.1
Creative Biolabs offers an innovative TRuC Cell platform that leverages advanced molecular biology and genetic engineering to develop superior T-cell therapies. The platform is designed to streamline the TRuC cell development process, from initial target antigen identification to final cell product validation. Creative Biolabs leverages advanced techniques to design and produce TRuC vectors. Scientists at our lab utilize advanced gene editing technologies, such as CRISPR and lentiviral vectors, to engineer the TRuC constructs into T cells. Our team employs proprietary cell culture and expansion technologies to ensure that TRuC cells expand effectively. Moreover, our rigorous validation process includes in vitro and in vivotesting to ensure that the engineered cells exhibit strong anti-tumor activity, minimal off-target effects, and long-lasting efficacy. We integrate various in vitro tests including flow cytometry, cytokine release assays, and cytotoxicity assays into our validation processes, providing comprehensive data that supports the safety and effectiveness of the engineered cells.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
